Trial · NCT02954523
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase I : Number of Patients With Drug-related Adverse Events as Assessed by CTCAEv4.0 | Phase I- Dasatinib Dose Level 2 | 0 | participants | ||
| Phase I : Number of Patients With Drug-related Adverse Events as Assessed by CTCAEv4.0 | Phase 1- Dasatinib Dose Level 1 | 3 | participants | ||
| Phase I : Number of Patients With Drug-related Adverse Events as Assessed by CTCAEv4.0 | Phase 1- Dasatinib Dose Level -1 | 0 | participants | ||
| Concentration of Osimertinib in Blood (Cmax) | Phase I- Dose Level 1 | 211.5 | Full Range 166 to 314 | nM/mL | |
| Concentration of Osimertinib in Blood (Cmax) | Phase 1- Dose Level 2 | 355 | Full Range 345 to 365 | nM/mL | |
| Concentration of Osimertinib in Blood (Cmax) | Phase 1- Dose Level -1 | 107 | Full Range 107 to 107 | nM/mL | |
| Progression-free Survival | Phase I- Dose Level 1 | 24.7 | Full Range 3.7 to 31.3 | months | |
| Progression-free Survival | Phase I- Dose Level 2 | 10.1 | Full Range 4.5 to 16.7 | months | |
| Progression-free Survival | Phase I- Dose Level -1 | 10.5 | Full Range 10.5 to 10.5 | months | |
| Overall Survival | Dose Level 1 | 36.1 | Full Range 23.5 to 46.6 | months | |
| Overall Survival | Phase I- Dose Level 2 | 16.9 | Full Range 7.4 to 36.6 | months | |
| Overall Survival | Phase I- Dose Level -1 | 28.7 | Full Range 28.7 to 28.7 | months | |
| Duration of Response | Phase I- Dose Level 1 | 27.8 | Full Range 18.6 to 31.9 | months | |
| Duration of Response | Phase I- Dose Level 2 | 12.2 | Full Range 8.4 to 15.9 | months | |
| Duration of Response | Phase 1 - Dose Level -1 | 8.7 | Full Range 8.7 to 8.7 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02954523/results